CHAPTER 21 Anesthesia for Immune-Mediated and Infectious Diseases





Introduction


The immune system plays a pivotal role in protecting an individual from many infectious agents and leading a healthy life. The abnormal response can result in life-threatening anaphy­laxis, and a weak or absence of response poses risks to individuals to acquire infection. The immune system’s exaggerated response can cause diseases involving multiple organ systems and may complicate anesthetic management. This chapter is an overview of common immune-mediated and infectious disorders.



Anaphylaxis


Anaphylaxis is a life-threatening manifestation of immersive antigen-antibody in which prior antigen detection has evoked antigen-specific IgE antibodies. Vasoactive mediators generated by mast cells and basophils are responsible for ana­phylaxis’s clinical symptoms. During anesthesia, anaphylaxis occurs 1 in 5,000 to 20,000 cases. The estimated mortality is 3 to 6%. Risk factors include:




  • Asthma history.



  • Female sex preponderance.



  • Multiple previous procedures.



  • Systemic mastocytosis.



Diagnosis


The clinical symptoms of anaphylaxis may resemble pulmonary embolism, acute myocardial infarction, aspiration or vasovagal reaction. Hypotension and cardiovascular arrest can be the only manifestations of anaphylaxis in general anesthesia patients. The plasma tryptase concentration is elevated within 1 to 2 hours of the alleged reaction, while the plasma histamine returns to baseline 30 to 60 minutes after the anaphylactic reaction. A positive intradermal test result (wheal and flare response) may be obtained, indicating the existence of unique IgE antibodies. The primary and secondary treatment of anaphylaxis is highlighted in Box 21.1.



Box 21.1 Management of anaphylactic reaction under anesthesia







































Primary Treatment


General measures




  • Inform the surgeon.



  • Call for help.



  • Stop administration of all drugs, colloids, and blood products.



  • Maintain airway and provide 100% oxygen.



  • Elevate legs if feasible.


Epinephrine administration




  • Titrate dose according to symptom severity and clinical response.



  • Adults: 10 µg to 1 mg by bolus, repeat every 1–2 min(s) as needed intravenous (IV).



  • Infusion: 0.05–1 µg/kg/min.



  • Children: 1–10 µg/kg bolus, repeat every 1–2 min(s) as needed.


Fluid therapy




  • Crystalloid: Normal saline 10–25 mL/kg over 20 min and more as needed.



  • Colloid: 10 mL/kg over 20 mins.


Anaphylaxis resistant to epinephrine




  • Glucagon: 1–5 mg bolus followed by 1–2.5 mg/h IV infusion.



  • Norepinephrine: 0.05–0.1 µg/kg/min IV infusion.



  • Vasopressin: 2–10 unit IV bolus followed by 0.01–0.1 unit/min IV infusion.


Secondary Treatment


Bronchodilators




  • β2-Agonist for symptomatic treatment of bronchospasm.


Antihistamines




  • Histamine 1 antagonist: Diphenhydramine 0.5–1 mg/kg IV.



  • Histamine 2 antagonist: Ranitidine 50 mg IV.


Corticosteroids




  • Adults: Hydrocortisone 250 mg IV or methylprednisolone 80 mg IV.



  • Children: Hydrocortisone 50–100 mg IV or methylprednisolone 2 mg/kg IV.

Only gold members can continue reading. Log In or Register to continue

Dec 11, 2022 | Posted by in ANESTHESIA | Comments Off on CHAPTER 21 Anesthesia for Immune-Mediated and Infectious Diseases

Full access? Get Clinical Tree

Get Clinical Tree app for offline access